Search PubMed⌕ Search

Biomedical subjects

R Whalen

Publications and source records attributed to R Whalen.

39 records · Page 3Linked to original sources

Systemic and local effects of heat dissipation in the thermally powered LVAS.

A thermally powered left ventricular assist system (LVAS) requires 20 W of heat dissipation either to the blood or to the surrounding tissues, such as the lung subcutaneous tissues. Postoperative systemic and local effects of heat dissipation were studied in 5 thermally powered LVASs and 2 heated blood pumps implanted in calves, and compared with 10 pneumatically powered left ventricular assist devices (LVADs). Postoperative mean temperatures of the heat dissipation group were as follows: 1. rectal (RT), 39.1 x 0.4 degrees C (NS versus control); 2. Lung interface, 41.6 +/- 0.6 degrees C (P less than 0.01 versus RT); 3. tissue interface, 40.2 +/- 1.2 degrees C (P less than 0.01 versus RT); and 4. blood, 39.2 +/- 0.8 degrees C (NS versus RT). There was no significant postoperative change in heart rate, respiratory rate, or rectal temperature between the two groups. No difference was shown between the two groups in hematologic parameters, plasma free hemoglobin, liver and renal function, fibrinogen levels, or coagulation processes at the same postoperative time. Heat dissipation to the pump-blood interface promoted a thinner neointima when compared with the nonheated surface. Angioneogenesis was observed in the tissue capsule adjacent to the heat dissipating surface. These results indicated that the thermal LVAS induced no deleterious local or systemic effects on recipient animals.

Air↗

In vivo evaluation of a permanently implantable thermal ventricular assist system.

The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988.

Animals↗